YOLFTbeta
Ever Supreme Bio Technology Co. Ltd

Ever Supreme Bio Technology Co. Ltd

6712 · TWO · Healthcare / Biotechnology

148.00TWD+2.50 (+1.72%)

Price History

Full chart

Market Stats

Previous Close145.50
Open148.00
Day Range147.00 – 149.00
52-Week Range120.95 – 184.00
Volume89.54K
Market Cap16.18B
P/E (TTM)32.66
Forward P/E0.00
EPS4.93
Dividend Yield2.07%
Beta0.31
50-Day Avg154.65
200-Day Avg145.73

About

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; chimeric antigen receptor immune cells, a chimeric antigen receptor immune cells product; and allogeneic bone-marrow stem cells, used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. In addition, the company develops allogeneic umbilical cord mesenchymal stem cells (UMSC01), used to treat cardiovascular diseases and strokes. Further, it engages in the sale of other health products and related businesses; and cell preparations and investment activities in biotechnology and medical industry businesses. Ever Supreme Bio Technology Co., Ltd was incorporated in 2016 and is based in Taichung, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOPo-Ching Lee
  • Employees0
  • HeadquartersNo. 30, Keya Road, Taichung, Taiwan, Taiwan
  • Websitehttps://www.ever-supreme.com.tw

Leadership

  • Po-Ching LeeFinancial Manager

Financials

Income Statement

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue70.60M438.84M627.51M758.39M933.81M1.02B
Growth (%)-+521.61%+42.99%+20.86%+23.13%+8.96%
Cost of Revenue88.54M193.36M212.96M273.64M273.77M296.18M
Gross Profit-17.95M245.48M414.56M484.75M660.04M721.33M
Gross Margin-25.42%55.94%66.06%63.92%70.68%70.89%
Operating Expense118.67M-151.96M149.94M-138.46M194.40M282.39M
Operating Income-136.62M397.44M264.61M623.22M465.64M438.94M
Operating Margin-193.52%90.57%42.17%82.18%49.86%43.14%
EBITDA-104.69M433.26M300.16M655.52M491.76M548.43M
EBITDA Margin-148.30%98.73%47.83%86.44%52.66%53.90%
Net Income-106.83M369.60M200.71M539.40M367.25M429.43M
Net Income Margin-151.32%84.22%31.99%71.12%39.33%42.20%
R&D109.25M84.14M90.69M99.11M147.22M238.16M
R&D as % of Total Revenue154.75%19.17%14.45%13.07%15.77%23.41%
Interest Expense778.00K618.00K510.00K201.00K125.00K917.00K
Interest Expense % of Total Revenue1.10%0.14%0.08%0.03%0.01%0.09%

Balance Sheet

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets858.32M2.02B1.97B2.08B2.14B2.00B
Total Liabilities77.56M124.83M181.45M232.96M341.82M477.80M
Total Equity780.76M1.90B1.79B1.84B1.79B1.53B
Cash68.88M641.10M353.57M336.44M301.68M222.16M
Total Debt43.21M34.42M17.86M5.90M--
Net Debt-25.67M-606.69M-335.71M-330.54M--

Cash Flow

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-138.47M135.69M319.20M421.74M440.34M536.35M
Financing Cash Flow28.59M733.36M-319.43M-500.47M--
Capital Expenditure60.82M4.65M5.59M5.83M5.56M5.72M
Free Cash Flow-199.29M131.04M313.61M415.91M434.78M530.62M
Dividends Paid--309.49M136.29M440.03M407.80M
FCF to OCF143.92%96.57%98.25%98.62%98.74%98.93%
Dividend Paid to FCF--98.69%32.77%101.21%76.85%

Earnings

Report DateMay 11, 2021Aug 11, 2021Nov 9, 2021Mar 24, 2022Aug 12, 2022Mar 30, 2023Mar 31, 2023Aug 11, 2023Nov 13, 2023Mar 29, 2024May 14, 2025Aug 12, 2025Nov 11, 2025Mar 16, 2026May 12, 2026Aug 12, 2026
EPS Estimate-0.310.330.590.830.640.770.890.800.861.050.610.931.271.830.870.94
EPS Actual-0.140.712.430.860.441.361.400.532.911.050.940.971.431.300.950.89
Surprise54.84%115.15%311.86%3.61%-31.25%76.62%56.49%-33.75%238.37%0.00%54.10%4.30%12.60%-28.96%9.20%-5.32%
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market-After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap16.18B
Enterprise Value15.45B
Trailing P/E32.66
Forward P/E0.00
Price / Sales14.96
Price / Book5.79
EPS4.93
Book Value27.93
Revenue (TTM)1.08B
Gross Profit (TTM)796.39M
EBITDA488.89M
Profit Margin43.78%
Operating Margin44.19%
Return on Equity23.35%
Return on Assets11.47%
Shares Outstanding100.49M
Shares Float72.43M
Beta0.31
Dividend Yield2.07%
Dividend Rate3.33
Payout Ratio72.94%

Dividends

20261×
3.33Apr 16, 2026
20251×
4.43Apr 30, 2025
20241×
5.19May 29, 2024
20231×
1.57May 29, 2023
20221×
3.58May 19, 2022

Stock Splits

  • May 14, 20261050:1000
  • Jun 3, 20251100:1000
  • May 29, 20241100:1000
  • May 29, 20231099.649:1000
  • May 19, 20221100:1000